News
NGM
1.590
-1.85%
-0.030
Weekly Report: what happened at NGM last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at NGM last week (0311-0315)?
Weekly Report · 03/18 09:06
Madrigal climbs amid hopes for new NASH drug; B. Riley upgrades
FDA approves Madrigal Pharmaceuticals' new drug for nonalcoholic steatohepatitis. Rezdiffra is the first U.S.-approved therapy for NASH. B. Riley upgrades the company's stock to Neutral from Sell. The company's shares are up 26% in the premarket.
Seeking Alpha · 03/15 12:19
Liver drug developers outperform as U.S. awaits first NASH drug
Liver drug developers outperform as U.S. Awaits first NASH drug approval. Madrigal Pharmaceuticals awaits FDA clearance for its lead asset resmetirom. The company's shares have soared 16% this year, outperforming the biopharma industry.
Seeking Alpha · 03/13 17:29
Ionis stock jumps as MASH drug succeeds in mid-stage trial
Ionis Pharmaceuticals stock jumps as MASH drug succeeds in mid-stage trial of its investigational drug to treat a type of fatty liver disease. Shares of Ionis Pharmaceuticals (IONS) jumped 7% premarket. The drug met primary endpoint in a Phase 2 study.
Seeking Alpha · 03/13 12:00
NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM
Former Attorney General of Louisiana Charles C. Foti, Jr. And the law firm of Kahn Swick & Foti are investigating the proposed sale of NGM Biopharmaceuticals, Inc. To affiliates of The Column Group, LP. Under the terms of the proposed transaction, shareholders will receive $1.55 in cash for each share. KSF is seeking to determine whether the consideration undervalues the Company.
Barchart · 03/13 10:44
Ngm Biopharmaceuticals Merger at Risk: Legal Hurdles Could Jeopardize Deal and Financial Stability
TipRanks · 03/13 06:00
NGM Biopharmaceuticals Cut to Market Perform From Outperform by Raymond James
Dow Jones · 03/12 09:34
Raymond James Downgrades NGM Biopharmaceuticals to Market Perform
Benzinga · 03/12 09:24
Raymond James downgrades NGM Biopharmaceuticals (NGM) to a Hold
NGM Biopharmaceuticals (NGM) received a Hold rating and price target from Raymond James analyst Steven Seedhouse yesterday. The company has a one-year high of $4.69 and a price target of $1.55. NGM is a company that is developing drugs to treat major diseases.
TipRanks · 03/12 08:36
NGM Biopharmaceuticals (NGM) Reports Q4 Loss, Lags Revenue Estimates
NASDAQ · 03/11 21:30
NGM Biopharmaceuticals GAAP EPS of -$0.33 misses by $0.01
NGM Biopharmaceuticals, Inc. GAAP EPS of -$0.33 misses by $0.01. Related party revenue from the collaboration with Merck Sharp & Dohme LLC. Cash, cash equivalents and short-term marketable securities were $144.2 million as of December 31, 2024.
Seeking Alpha · 03/11 21:09
BRIEF-NGM Biopharmaceuticals Q4 Net Income USD -27.67 Million
Reuters · 03/11 20:05
*NGM Biopharmaceuticals 4Q Loss/Shr 33c >NGM
Dow Jones · 03/11 20:05
Press Release: NGM Bio Provides Recent Business -2-
GM Bio reported a net loss of $27.7 million for the fourth quarter and full year of 2023. The company's collaboration with Merck Sharp & Dohme ends on March 31, 2024. NGM Bio is focused on discovering and developing novel, life-changing medicines.
Dow Jones · 03/11 20:05
Press Release: NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results
NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results. The company reports $144.2 million in cash, cash equivalents and marketable securities as of December 31, 2023. NGM Biopharmaceuticals, Inc. Is a biotechnology company focused on discovering and developing transformative drugs.
Dow Jones · 03/11 20:05
*NGM Biopharmaceuticals 4Q Loss $27.7M >NGM
Dow Jones · 03/11 20:05
NGM Biopharmaceuticals: Q4 Earnings Snapshot
NGM Biopharmaceuticals Inc. Reported a loss of $27.7 million in its fourth quarter. The biotechnology company posted revenue of $165,000 in the period. The results exceeded Wall Street expectations. NGM says it had a fourth quarter loss of 33 cents per share.
Barchart · 03/11 15:27
Weekly Report: what happened at NGM last week (0304-0308)?
Weekly Report · 03/11 09:06
Why NGM Biopharmaceuticals (NGM) Might Surprise This Earnings Season
NASDAQ · 03/07 14:15
More
Webull provides a variety of real-time NGM stock news. You can receive the latest news about Ngm Biopharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About NGM
NGM Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company's biology-driven and therapeutic area agnostic discovery engine has produced a diverse pipeline of product candidates spanning oncology, liver and metabolic disease and retinal disease. Its pipeline candidates include NGM707: ILT2/ILT4 Dual Antagonist Antibody for the Potential Treatment of Solid Tumors, Including microsatellite stable colorectal cancer patients; Aldafermin: Engineered Analog of Human Hormone FGF19 for the Potential Treatment of primary sclerosing cholangitis, and NGM120: glial cell-derived neurotrophic factor receptor alpha-like Antagonist for the Potential Treatment of Hyperemesis Gravidarum. It is conducting an open-label Phase 1/2 clinical trial evaluating NGM707 as a monotherapy and in combination with pembrolizumab for the treatment of patients with advanced or metastatic solid tumors. Its programs, NGM438 and NGM831, are being studied in a Phase 1/2 trial in combination with pembrolizumab.